PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12437495

Current oral treatments for erectile dysfunction.

J S Kalsi·S Cellek·A Muneer·P D Kell·D J Ralph·S Minhas
View original source ↗Export metadata ↓

Abstract

Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse. It is a significant male health problem of global dimensions affecting approximately 150 million men worldwide. A broad range of options are currently available for the management of ED. They include oral agents (phosphodiesterase 5 inhibitors, dopamine agonists and alpha-receptor blocking drugs), intracavernosal injection (papaverine, phentolamine, prostaglandin E1, vasoactive intestinal peptide), transurethral vasoactive agents (prostaglandin E1), vacuum erection devices, vascular surgery and penile prostheses. Here we review the physiology of penile erection and the currently available oral preparations. In addition, novel therapeutic strategies to improve erectile function are discussed.

Explore related subjects

3',5'-Cyclic-GMP PhosphodiesterasesAdministration, OralAdrenergic alpha-AntagonistsCyclic Nucleotide Phosphodiesterases, Type 5Dopamine AgonistsErectile DysfunctionGuanylate CyclaseHumansIntracellular Signaling Peptides and ProteinsMalePenisPhosphodiesterase InhibitorsProtein Serine-Threonine KinasesReceptors, Cytoplasmic and NuclearSoluble Guanylyl Cyclaserho-Associated KinasesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J S Kalsi, S Cellek, A Muneer, P D Kell, D J Ralph, S Minhas. 2002. Current oral treatments for erectile dysfunction.. https://doi.org/10.1517/14656566.3.11.1613

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.

Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, vardenafil, or tadalafil) or phosphorylation by cyclic nucleotide-dependent protein kinase causes an apparent conformational change in PDE5, as indicated by a shift in migration on non-denaturing PAGE gels and an altered pattern of tryptic digestion. Combination of cGMP and a PDE5 inhibitor or phosphorylation does not cause a further gel shift or change in tryptic digest. Phosphorylation of PDE5 is stimulated by inhibitors, and combination of cGMP and inhibitor does not cause further phosphorylation. Dephosphorylation of PDE5 by either purified phosphoprotein phosphatase-1 or -2A catalytic subunit or by a crude phosphatase mixture is not affected by cGMP or inhibitors, suggesting that phosphorylation itself maintains conformational exposure of the phosphorylation site. The combined results imply that cGMP binding to the catalytic site initiates negative feedback control of many cellular cGMP signaling pathways by directly stimulating phosphorylation and activation of PDE5; by exploiting this molecular mechanism, PDE5 inhibitors stimulate their own potencies.

3',5'-Cyclic-GMP Phosphodiesterases↗
PubMed2007

Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.

The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.

3',5'-Cyclic-GMP Phosphodiesterases↗